-
6 Popular Peptides May Soon Be Easier to Access, Report Suggests
A new report highlights that several popular peptides could soon become more accessible to consumers, reflecting growing mainstream interest in peptide therapies. Easier access could mean more people benefiting from these emerging treatments under proper guidance.
-
FDA Panel Vote Signals Potential for Easier Access to Popular Peptides
A recent FDA panel vote could pave the way for millions of Americans to gain easier access to popular peptide compounds, marking a potentially significant shift in regulatory approach.
-
GLP-1 Peptide Therapy Shows Promise in Reducing Heavy Drinking, Trial Finds
Altimmune’s GLP-1-based drug demonstrated a reduction in heavy drinking days among participants with alcohol use disorder in a recent clinical trial, opening a potential new avenue for treatment.
-
FDA Signals Broader Peptide Access—Minnesota Pharmacies Gear Up
Reports indicate the FDA may expand availability of certain peptides, prompting Minnesota compounding pharmacies to prepare for increased demand and patient access.
-
FDA Advisory Panel Recommends Easing Regulations for Certain Peptides
An FDA advisory panel has recommended loosening regulatory restrictions on select peptides, responding to growing public and scientific interest in this category of compounds.
-
FDA Peptide Review Could Expand Access Through Compounding Pharmacies
A new FDA review of peptide compounds may open the door for compounding pharmacies to prepare more peptide-based therapies, potentially widening patient access to these treatments.
-
FDA Advisory Committee Backs Continued Access to Compounded Peptides
An FDA advisory committee voted in favor of preserving access to certain compounded peptides, a notable win for patients and practitioners who rely on these therapies.
-
FDA Advisory Panel Narrowly Endorses Several Peptides Linked to RFK Jr.’s Health Agenda
An FDA advisory committee voted narrowly in favor of several peptide compounds that have drawn public attention from Health and Human Services Secretary Robert F. Kennedy Jr., though the panel’s recommendation is nonbinding and final approval decisions remain with the agency.
-
HHS Signals Shift Toward Easing Restrictions on Psychedelic Research
Reporting indicates that Health and Human Services Secretary Robert F. Kennedy Jr. is following through on pledges to reduce regulatory barriers that have long limited research into psychedelic compounds. The developments could reshape how these substances are studied and potentially used in clinical settings.
-
Experimental Peptide Shows Early Promise in Spinal Cord Nerve Repair Trial
A peptide-based therapy being tested in a clinical trial has reportedly shown signs of nerve repair in patients with spinal cord injuries, according to a recent industry report. Researchers caution that results remain early-stage and require further validation.